Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold
作者:Min Wang、Shan Xu、Huajun Lei、Caolin Wang、Zhen Xiao、Shuang Jia、Jia Zhi、Pengwu Zheng、Wufu Zhu
DOI:10.1016/j.bmc.2017.09.003
日期:2017.10
Four series of Sorafenib derivatives bearing pyrazole scaffold (8a–m, 9a–c, 10a–e and 11a) were synthesized and characterized by NMR and MS. All of the target compounds were evaluated for the cytotoxicity against A549, HepG2, MCF-7, and PC-3 cancer cell lines and some selected compounds were further evaluated for the activity against VEGFR-2/KDR, BRAF, CRAF, c-Met, EGFR and Flt-3 kinases. Compounds
合成了四个带有吡唑支架的索拉非尼衍生物系列(8a – m,9a – c,10a – e和11a),并通过NMR和MS进行了表征。评估了所有目标化合物对A549,HepG2,MCF-7和PC-3癌细胞的细胞毒性,并对一些选定的化合物进一步评估了对VEGFR-2 / KDR,BRAF,CRAF,c-Met的活性,EGFR和Flt-3激酶。化合物8b和8i比化合物8h,9a更具活性,尤其是IC 50化合物8b对VEGFR-2激酶的值是0.56μM。化合物8b对c-Met具有中等至良好的活性,对CRAF,c-Met,EGFR,Flt-3激酶具有中等至无活性。11种目标化合物表现出中等至良好的抗肿瘤活性。最有前途的化合物8b对A549,HepG2和MCF-7细胞系具有很强的抗肿瘤活性,IC 502.84±0.78μM,1.85±0.03μM和1.96±0.28μM的值相当于索拉非尼(2.92±0.68μM,3